Home page | VACCINE CONGRESS 2024VACCINE CONGRESS 2024

Renowned Speakers

Orien L Tulp

University of Science Arts and Technology, USA

Cecilia Castro

University of Minho, Portugal

Caryn Fenner

Afrigen Biologics, South Africa

Sandra Gunhild Erika Möhr

REHAB Basel, Switzerland

Amina Tebaa

Pharmacovigilance Responsible in Public Health Programs, Morocco

J. Santiago Mejia

Lead Scientist Oxford Immunotech, USA

Natalia Romanenkova

Virological supervisor of WHO Subnational Laboratory Pasteur Institute in St. Petersburg, Russia

Bing-Huei Chen

Chair Professor Fu Jen University, Taiwan

Recommended Global Vaccines Webinars & Conferences

Europe & UK

Asia Pacific & Middle East

Canada

VACCINE CONGRESS 2024

About VACCINE CONGRESS 2024

The highly anticipated "4^th International Conference on Vaccine Research" is scheduled to take place from September 09-10, 2024, in the vibrant city of Madrid, Spain. This landmark event promises to be a hybrid experience, seamlessly blending in-person and virtual components to accommodate a diverse global audience. VACCINE CONGRESS 2024 aims to provide an inclusive platform for scientists, researchers, and vaccine advocates to converge, exchange ideas, and collectively advance the field of vaccine research with the theme of "Expanding Present Vaccine Research Outcomes in the Wake of Pandemic."

The agenda for VACCINE CONGRESS 2024 has been meticulously crafted, spanning two days dedicated to in-depth exploration of various facets of vaccine research. The inaugural day will kick off with a grand opening ceremony, setting an intellectually stimulating atmosphere. Esteemed keynote speakers from the realm of vaccine research will share their expertise, offering valuable insights into the latest advancements and challenges in vaccine development. Subsequent sessions will encompass a diverse array of scientific discussions, panel talks, and workshops, covering topics such as vaccine efficacy, immunology, public health implications, and ethical considerations.

In the face of ongoing health challenges, the significance of vaccine research has never been more pronounced. VACCINE CONGRESS 2024 stands at the forefront of this critical dialogue, propelling progress in vaccine science and shaping the trajectory of global health. We invite you to embark on this exciting journey with us at VACCINE CONGRESS 2024 and contribute to the collective effort of building a healthier, more resilient world.

Why Attend?

This is your prime opportunity to engage with the largest gathering of professionals dedicated to vaccine research and development worldwide. Our diverse membership spans the globe, attracting individuals interested in the latest advancements in vaccine science and technology. The conference features renowned speakers, showcasing the latest methods, discoveries, and breakthroughs in vaccine research, including:

Internationally recognized experts presenting cutting-edge research in vaccine development, immunology, and public health.
Access to the most recent innovations in vaccine technology, including advancements in vaccination techniques and immunization strategies.
In-depth discussions on topics such as vaccine efficacy, safety, and distribution, as well as ethical considerations in vaccine development.
Opportunities to network with leading scientists, researchers, and practitioners in the field of vaccine research and development.

Join us for this two-day conference to:

Present your research findings, share knowledge, and contribute to the advancement of vaccine science.
Engage in discussions with pioneers in vaccine research, exchanging ideas and perspectives on the current challenges and opportunities in the field.
Participate in interactive debates, plenary sessions, and workshops to gain insights into the latest trends and developments in vaccine research.

This conference provides a unique platform for professionals in the field of vaccine research to come together, exchange ideas, and collaborate on advancing vaccine science for the betterment of global health. Don't miss this opportunity to be part of the conversation and contribute to shaping the future of vaccine research and development.

Target Audience

Vaccine Researchers
Immunologists
Microbiologists
Public Health Specialists
Epidemiologists
Virologists
Pharmacologists
Vaccine Developers
Clinical Researchers
Healthcare Administrators
Policy Makers in Public Health
Pharmaceutical Industry Representatives
Medical Practitioners
Primary Care Physicians
Specialists in Infectious Diseases
Pediatricians
Internal Medicine Physicians
Nurses and Nurse Practitioners
Health Educators
Medical Students and Residents
Biomedical Engineers
Biostatisticians
Ethicists in Healthcare
Patient Advocates
Global Health Organizations
Academic Institutions in Health Sciences
Government Health Agencies
Non-Governmental Organizations (NGOs)
Vaccine Manufacturers
Biotechnology Companies
Clinical Trial Organizations
Medical Device Companies
Healthcare Technology Providers
Research Funding Agencies

Sessions & Tracks

Track 1. COVID19 Vaccines

COVID19 vaccines are pivotal tools in combating the global pandemic caused by the SARSCoV2 virus. Utilizing various technologies such as mRNA, viral vector, and protein subunit, these vaccines aim to induce immunity against the virus, thereby preventing severe illness and transmission.

mRNA vaccines
Vector vaccines
Vaccine efficacy
Vaccine distribution
Vaccine hesitancy
Booster doses

Related Global Conferences:

Related Societies:

Europe:

European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society; Deutsche Gesellschaft fur Immunology

USA:

American Academy of Pediatrics ; American College Health Association ; Association of Immunization Managers ; Association for Professionals in Infection Control and Epidemiology

Asia and Middle-East:

Asia Pacific Association of Allergy, Asthma, and Clinical Immunology ; Asia Pacific Association of Pediatric Allergy, Respirology and Immunology ; Commonwealth of Independent States Society of Allergology and Immunology

Track 02: Vaccines Epidemiology

Vaccines epidemiology – Vaccines - A scientific field that works with testing methods and methods involved in vaccine testing is vaccine epidemiology. The overall purpose of the research field is to provide an understanding of the various methods and techniques involved in evaluating vaccines.

There is a growing increase in vaccines that guarantee life-saving interventions, and the use of epidemiological vaccines maximizes the benefits of this type of primary prevention.

Vaccination
Immunization
Herd immunity
Vaccine efficacy
Vaccine safety
Vaccine-preventable diseases

Related Global Conferences:

Related Societies:

Europe:

European Society for Pediatric Infectious Diseases; European Union Geriatric Medicine Society; European Federation of Immunological Societies; European Academy of Allergy and Clinical Immunology; Royal Society of London; Epidemiological Society of London; Edward Jenner Society

USA:

The Anti-Vaccination Society of America ; Infectious Diseases Society of America; Association of Immunization Managers; Clinical Immunology Society

Asia and Middle-East:

Japanese Society for Immunology; Singaporean Society for Immunology; Australasian Society of Clinical Immunology and Allergy

Track 03: Vaccines Immunology

Immunization is a worldwide wellbeing and advancement example of overcoming adversity, saving large number of lives each year. Antibodies diminish dangers of getting a sickness by working with your body's normal safeguards to construct security. At the point when you get an antibody, your resistant framework reacts.

We currently have immunizations to forestall in excess of 20 perilous illnesses, helping individuals of any age live more, better lives. Vaccination as of now forestalls 2-3 million passing consistently from sicknesses like diphtheria, lockjaw, pertussis, flu and measles.

Immune response
Antibodies
Antigens
Memory cells
B cells
T cells
Adaptive immunity
Innate immunity
Humoral immunity

Related Global Conferences:

Related Societies:

Europe:

European Academy of Pediatrics; European Malaria Foundation (e-malaria Foundation); European Malaria Vaccine Development ; European malaria Vaccine Initiative

USA:

Autism Science Foundation ; Childhood Influenza Immunization Coalition ;Edward Jenner Vaccine Society; Global Polio Eradication Initiative

Asia and Middle-East:

Lebanese Society of Allergy and Immunology; Moldavian Society of Allergology & Immunology; Moroccan Society of Allergology and Clinical Immunology

Track 4. Vaccine Safety

Vaccine safety is paramount for public health programs. Rigorous monitoring, from preclinical trials through postmarket surveillance, ensures adverse events following immunization (AEFI) are promptly detected and managed. Pharmacovigilance systems track vaccine safety in real-world scenarios, maintaining public trust.

Bcell immunity
Tcell immunity
Immune memory
Vaccineinduced immune responses
Immune correlates of protection

Related Global Conferences:

Related Societies:

Europe:

European Academy of Allergy and Clinical Immunology ; European Molecular Biology Laboratory ; Medical Research Council ; Royal Society of London; Epidemiological Society of London; Edward Jenner Society

USA:

Hepatitis B Foundation ; Infectious Diseases Society of America ; National Adult and Influenza Immunization Summit ; National Foundation for Infectious Diseases ; Pediatrics Infectious Diseases Society

Asia and Middle-East:

Russian Association of Allergology and Clinical Immunology; Turkish National Society of Allergy and Clinical Immunology; Ukrainian Association of Allergologists and Clinical Immunologists

Track 5. Novel Vaccine Platforms

Innovative vaccine platforms, including mRNA, DNA, viral vectors, and recombinant protein vaccines, offer promising avenues for vaccine development. These platforms enhance efficacy, scalability, and antigen presentation, leading to broader vaccine applications.

DNA vaccines
Viruslike particles (VLPs)
Recombinant protein vaccines
Synthetic vaccines
Nanoparticle vaccines

Related Global Conferences:

Related Societies:

Europe:

European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society; Deutsche Gesellschaft fur Immunology

USA:

American Academy of Pediatrics ; American College Health Association ; Association of Immunization Managers ; Association for Professionals in Infection Control and Epidemiology

Asia and Middle-East:

Asia Pacific Association of Allergy, Asthma and Clinical Immunology ; Asia Pacific Association of Pediatric Allergy, Respirology and Immunology ; Commonwealth of Independent States Society of Allergology and Immunology

Track 6. Immunology of Vaccines

Understanding vaccine induced immune responses is critical for optimizing vaccine design and efficacy. Vaccines stimulate both humoral and cellular immunity, leading to the production of antibodies and memory cells. Insights into immunological mechanisms guide vaccine development and administration strategies.

Bcell immunity
Tcell immunity
Immune memory
Vaccineinduced immune responses
Immune correlates of protection

Related Global Conferences:

Related Societies:

Europe:

Croatian Society of Allergology and Clinical Immunology; Czech Society of Allergology and Clinical Immunology; Finnish Society of Allergology and Clinical Immunology; French Society of Allergology and Clinical Immunology

USA:

Panamanian Association of Allergology and Clinical Immunology; Paraguayan Society of Allergy, Asthma, and Immunology; Peruvian Society of Allergy and Immunology; Venezuelan Society of Allergy, Asthma and Immunology

Asia and Middle-East:

Philippine Society of Allergy, Asthma and Immunology; Taiwan Academy of Pediatric Allergy Asthma Immunology; Vietnam Association of Allergy, Asthma and Clinical Immunology

Track 7. Vaccine Manufacturing

Efficient vaccine manufacturing is essential for global vaccine supply. Modern manufacturing technologies, such as cell based and recombinant methods, enhance scalability and flexibility. Supply chain management ensures timely distribution of vaccines to meet public health demands.

Scale up production
Vaccine supply chains
Technology transfer
Good Manufacturing Practices (GMP)
Vaccine stability and storage

Related Global Conferences:

Related Societies:

Europe:

USA:

Panamanian Association of Allergology and Clinical Immunology; Paraguayan Society of Allergy, ; Peruvian Society of Allergy and Immunology; Venezuelan Society of Allergy, Asthma and Immunology

Asia and Middle-East:

Philippine Society of Allergy, Asthma and Immunology; Taiwan Academy of Pediatric Allergy Asthma Immunology; Vietnam Association of Allergy, Asthma and Clinical Immunology

Track 8. Vaccine Delivery Systems

Effective vaccine delivery systems ensure widespread immunization coverage. Innovations in delivery technologies, including needle free injections, microneedle patches, and oral vaccines, enhance vaccine accessibility and acceptability.

Needlefree delivery
Microneedle patches
Oral vaccines
Intranasal vaccines
Biodegradable polymers

Related Global Conferences:

Related Societies:

Europe:

European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society; Deutsche Gesellschaft fur Immunologie

USA:

American Academy of Pediatrics ; American College Health Association ; Association of Immunization Managers ; Association for Professionals in Infection Control and Epidemiology

Asia and Middle-East:

Track 9. Vaccine Hesitancy

Vaccine hesitancy poses a significant challenge to public health efforts. Understanding the drivers of hesitancy, such as misinformation, mistrust, and complacency, is crucial for implementing targeted interventions to promote vaccine acceptance.

Vaccine misinformation
Trust in vaccines
Vaccine confidence interventions
Cultural and societal factors
Vaccine communication strategies

Related Global Conferences:

Related Societies:

Europe:

British Society for Immunology; Microbiology Society , London; Royal Society of London; Epidemiological Society of London ; Edward Jenner Society; Society for Applied Microbiology ; European Society of Clinical Microbiology and Infectious Diseases

USA:

The Federation of Clinical Immunology Societies; The American Association of Immunologists; American Society for Microbiology; Colombian Allergy, Asthma and Immunology Association; Canadian Society for Immunology

Asia and Middle-East:

Indian society of Allergy, Asthma and Clinical Immunology; Australasian Society of Clinical Immunology and Allergy; Bangladesh Society of Allergy and Immunology

Track 10. Global Vaccine Access

Ensuring equitable access to vaccines worldwide is essential for achieving global health security. Collaborative efforts between governments, international organizations, and pharmaceutical companies aim to address barriers to access, such as supply shortages and distribution inequities.

Vaccine equity
COVAX initiative
Access to affordable vaccines
Supply chain logistics
Addressing barriers to access

Related Global Conferences:

Related Societies:

Europe:

Swiss Society for Microbiology; Societies; International; International Union of Immunological Society; Royal Society of London; Epidemiological Society of London; Edward Jenner Society

USA:

Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy,Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clinical Immunology

Asia and Middle-East:

Indonesian Society of Allergy and Immunology; Korean Academy of Asthma, Allergy and Clinical Immunology; Malaysian Society of Allergy and Immunology

Track 11. Paediatric Vaccines

Paediatric vaccines protect children against various infectious diseases, reducing morbidity and mortality. Comprehensive vaccination schedules recommended by health authorities target diseases like measles, mumps, rubella, and polio.

Childhood immunization schedule
Combination vaccines
Vaccine safety in children
Immunization coverage rates
Vaccines for new-borns and infants

Related Global Conferences:

Related Societies:

Europe:

European Academy of Pediatrics; European Malaria Foundation (e-malaria Foundation); European Malaria Vaccine Development ; European malaria Vaccine Initiative

USA:

Autism Science Foundation ; Childhood Influenza Immunization Coalition ; Edward Jenner Vaccine Society; Global Polio Eradication Initiative

Asia and Middle-East:

Lebanese Society of Allergy and Immunology; Moldavian Society of Allergology & Immunology; Moroccan Society of Allergology and Clinical Immunology

Track 12. Geriatric Vaccines

Geriatric vaccines safeguard the elderly population against vaccine preventable diseases. Vaccines targeting influenza, pneumococcal disease, and shingles reduce the burden of illness and complications in older adults.

Vaccines for older adults
Immunosenescence
Vaccine effectiveness in the elderly
Vaccination strategies for seniors
Addressing age-related health conditions

Related Global Conferences:

Related Societies:

Europe:

USA:

Asia and Middle-East:

Russian Association of Allergology and Clinical Immunology; Turkish National Society of Allergy and Clinical Immunology; Ukrainian Association of Allergologists and Clinical Immunologists

Track 13. Vaccine Adjuvants

Vaccine adjuvants enhance immune responses to antigens, improving vaccine efficacy and duration of protection. Adjuvants such as aluminum salts, oilinwater emulsions, and tolllike receptor agonists stimulate innate immunity, leading to robust adaptive immune responses.

Aluminum salts
Liposomes
Toll like receptor agonists
Adjuvant systems
Enhancing immune responses

Related Global Conferences:

Related Societies:

Europe:

USA:

Asia and Middle-East:

Russian Association of Allergology and Clinical Immunology; Turkish National Society of Allergy and Clinical Immunology; Ukrainian Association of Allergologists and Clinical Immunologists

Track 14. Vaccine Development for Emerging Diseases

Rapid vaccine development is critical in response to emerging infectious diseases. Innovative approaches, including platform technologies and accelerated clinical trials, enable timely vaccine deployment to contain outbreaks and prevent pandemics.

Rapid response platforms
Preclinical studies
Pandemic preparedness
Target identification
Adaptive clinical trial design

Related Global Conferences:

Related Societies:

Europe:

European Society for Pediatric Infectious Diseases; European Union Geriatric Medicine Society; European Federation of Immunological Societies; European Academy of Allergy and Clinical Immunology

USA:

The Anti-Vaccination Society of America ; Royal Society of London; Epidemiological Society of London; Edward Jenner Society ; Infectious Diseases Society of America; Association of Immunization Managers; Clinical Immunology Society

Asia and Middle-East:

Japanese Society for Immunology; Singaporean Society for Immunology; Australasian Society of Clinical Immunology and Allergy

Track 15. Vaccine Immunogenicity

Vaccine immunogenicity refers to the ability of a vaccine to induce an immune response. Factors influencing immunogenicity include vaccine formulation, antigen design, and host factors such as age and immune status. Understanding immunogenicity is essential for evaluating vaccine efficacy and optimizing vaccination strategies.

Humoral immune response
Cellular immune response
Immunogenicity assays
Correlates of protection
Vaccine antigen design

Related Global Conferences:

Related Societies:

Europe:

British Society for Allergy and Clinical Immunology; British Society for Histocompatibility and Immunogenetics; European Federation of Immunological Societies; European Academy of Allergology and Clinical Immunology

USA:

Voices for Vaccines ; National Institute of Allergy and Infectious Disease ; American Public Health Association ; American Association for the Advancement of Science ; American Society for Microbiology .

Asia and Middle-East:

Australasian Society for Immunology; Australasian Society of Clinical Immunology and Allergy; Israel Association of Allergy and Clinical Immunology; Jordanian Society for Allergy and Clinical Immunology; Japanese Society for Immunology

Track 16. Vaccine Policy and Regulation

Robust vaccine policies and regulations govern vaccine development, approval, and distribution. Regulatory agencies ensure vaccines meet safety and efficacy standards through rigorous evaluation of clinical data and manufacturing processes.

Regulatory approval processes
Vaccine licensure
Vaccine mandates
National immunization programs
Postmarketing surveillance

Related Global Conferences:

Related Societies:

Europe:

Swiss Society for Microbiology; Federation of European Microbiological Societies; International Society of Vaccines; Royal Society of London; Epidemiological Society of London; Edward Jenner Society; International Union of Immunological Society

USA:

Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clincial Immunology

Asia and Middle-East:

Indonesian Society of Allergy and Immunology ; Korean Academy of Asthma , Allergy and Clinical Immunology; Malaysian Society of Allergy and Immunology

Track 17. Next Generation Vaccines

Nextgeneration vaccines leverage advanced technologies to improve vaccine efficacy, safety, and delivery. Innovations such as mRNA vaccines, nanoparticlebased vaccines, and synthetic biology offer promising avenues for developing vaccines against challenging pathogens.

Personalized vaccines
Synthetic biology approaches
Multivalent vaccines
Universal vaccines
mRNA vaccine platforms

Related Global Conferences:

Related Societies:

Europe:

European Society for Pediatric Infectious Diseases; European Union Geriatric Medicine Society; European Federation of Immunological Societies ; European Academy of Allergy and Clinical Immunology

USA:

The Anti-Vaccination Society of America; Royal Society of London ; Epidemiological Society of London; Edward Jenner Society; Infectious Diseases Society of America; Association of Immunization Managers; Clinical Immunology Society

Asia and Middle-East:

Japanese Society for Immunology; Singaporean Society for Immunology; Australasian Society of Clinical Immunology and Allergy

Track 18. Vaccine Clinical Trials

Vaccine clinical trials assess the safety, immunogenicity, and efficacy of candidate vaccines in human populations. Phases of clinical trials, from initial testing in small groups to largescale efficacy trials, provide critical data for regulatory approval and public health decisionmaking.

Phase I, II, III trials
Randomized controlled trials
Vaccine efficacy studies
Safety monitoring
Postlicensure studies

Related Global Conferences:

Related Societies:

Europe:

Swiss Society for Microbiology; Federation of European Microbiological Societies; International Society of Vaccines; International Union of Immunological Society; Royal Society of London; Epidemiological Society of London; Edward Jenner Society

USA:

Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clin Related Societies

Europe:

Swiss Society for Microbiology ; Federation of European Microbiological Societies; International Society of Vaccines; International Union of Immunological Society; Royal Society of London; Epidemiological Society of London; Edward Jenner Society

Track 19. Vaccine Financing

Sustainable financing mechanisms are essential for vaccine research, development, and distribution. Publicprivate partnerships, donor funding, and innovative financing instruments support vaccine development efforts and ensure equitable access to vaccines worldwide.

Global vaccine funds
Publicprivate partnerships
Vaccine procurement
Health insurance coverage
Costeffectiveness analyses

Related Global Conferences:

Related Societies:

Europe:

USA:

Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clin Related Societies

Europe:

Swiss Society for Microbiology ; Federation of European Microbiological Societies; International Society of Vaccines; International Union of Immunological Society; Royal Society of London; Epidemiological Society of London; Edward Jenner Society

Track 20. Vaccine Equity

Vaccine equity aims to ensure fair and impartial distribution of vaccines to all populations, regardless of socioeconomic status or geographic location. Addressing barriers to access, such as affordability, transportation, and vaccine hesitancy, promotes equitable vaccine coverage and reduces health disparities.

Addressing disparities in access
Community outreach programs
Health equity initiatives
Vaccine allocation strategies
Equity in clinical trials

Related Global Conferences:

Related Societies:

Europe:

USA:

Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clincial Immunology

Asia and Middle-East:

Indonesian Society of Allergy and Immunology ; Korean Academy of Asthma , Allergy and Clinical Immunology; Malaysian Society of Allergy and Immunology

Track 21. Vaccine Surveillance

Vaccine surveillance systems monitor vaccine preventable diseases and vaccine safety in real-time. Surveillance data inform public health interventions, outbreak response efforts, and vaccine policy decisions to protect population health.

Disease surveillance systems
Adverse event surveillance
Vaccine preventable disease monitoring
Vaccine coverage surveillance
Real-time monitoring systems

Related Global Conferences:

Related Societies:

Europe:

USA:

Asia and Middle-East:

Russian Association of Allergology and Clinical Immunology; Turkish National Society of Allergy and Clinical Immunology; Ukrainian Association of Allergologists and Clinical Immunologists

Track 22. One Health Approach

The One Health approach recognizes the interconnectedness of human, animal, and environmental health. Vaccines developed using a One Health framework address zoonotic diseases and promote collaboration across sectors to mitigate emerging infectious disease threats.

Zoonotic disease prevention
Humananimalenvironment interface
Crossspecies transmission
Ecosystem health
Interdisciplinary collaboration

Related Global Conferences:

Related Societies:

Europe:

USA:

Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clincial Immunology

Asia and Middle-East:

Indonesian Society of Allergy and Immunology ; Korean Academy of Asthma , Allergy and Clinical Immunology; Malaysian Society of Allergy and Immunology

Market Analysis

VACCINE CONGRESS 2024 The vaccines market is an important aspect of the healthcare industry, with an expected value of USD 28.28 billion by 2026, according to research by Technavio. This market includes two main types of vaccines: prophylactic vaccines, which help prevent diseases, and therapeutic vaccines, which are used to treat existing illnesses.

The market is segmented by geography, including North America, Europe, Asia, and the Rest of World (ROW). Various vendors are involved in the production and distribution of vaccines, including Astellas Pharma Inc., AstraZeneca Plc, and GlaxoSmithKline Plc, among others. It is crucial for individuals to have access to vaccines to prevent the spread of diseases and maintain overall health. The growing vaccines market indicates the importance of investing in and researching new vaccines to protect public health.

Benefits of Participation

Types of participation

VACCINE CONGRESS 2024, provides the participants with different modes or ways to participate under either Academic / Student / Business Category

Keynote speaker: 45-50 minutes
Speaker (oral presentation): 25-30 minutes (only one person can present)
Speaker (workshop): 45-50 minutes (more than 1 can present)
Speaker (special session): 45-50 minutes (more than 1 can present)
Speaker (symposium): more than 45 minutes (more than 1 can present)
Delegate (only registration): will have access to all the sessions with all the benefits of registration
Poster presenter: can present a poster and enjoy the benefits of delegate
Remote attendance: can participate via virtual mode or video presentation or e-poster presentation
Exhibitor: can exhibit his/her/their company’s products by booking exhibitor booths of different sizes
Media Partner
Sponsor
Collaborator

Advantages of Participating in VACCINE CONGRESS 2024:

For Attendees:

1. Global Visibility: Your profile and abstract pages indexed by Google provide global visibility, fostering recognition in the vaccine research community.

2. Accessible Research: Our Library of Abstracts attracts over 30,000 visits monthly, facilitating exposure to cutting-edge research and attracting scholars and speakers.

3. Interactive Sessions: Engage in interactive meetings, ideal for networking and collaboration, especially for research teams.

4. Thought Leadership Exchange: Meet and exchange ideas with thought leaders in vaccine research, fostering intellectual growth and collaboration.

5. Recognition and Awards: Opportunities for receiving awards such as Young Scientist Award and Best Poster Certificates, acknowledging excellence in research.

6. Personalized Engagement: Engage in one-on-one discussions with distinguished speakers and keynote presenters, gaining personalized insights and inspiration.

7. Keynote Insights: Attend keynote presentations to gain insights from leading authorities in vaccine research, staying abreast of the latest discoveries.

Benefits for Speakers:

1. Publication Opportunity: All accepted abstracts will be published in reputable journals, contributing to scholarly dissemination and recognition.

2. Global Recognition: Gain admiration and recognition on a global scale for your contributions to vaccine research.

3. Professional Development: Discover cutting-edge analysis and advancements in the field, enriching your expertise and skills.

4. Networking and Collaboration: Forge lifelong connections through social and networking activities, fostering collaboration and growth.

5. Enhanced Visibility: Promote your research profile through distribution of abstract books and flyers, reaching a wide audience and enhancing visibility.

6. Diversified Learning: Explore new topics and studies beyond your primary focus, enriching your knowledge and broadening your research horizons.

Benefits for Delegates:

1. Knowledge Enhancement: Gain increased knowledge and understanding in vaccine research, supporting professional development.

2. Refreshing Experience: Attending conferences provides a refreshing and energizing experience, revitalizing your passion for research and learning.

3. Innovation Support: Support the development of new approaches and philosophies in vaccine research, contributing to industry advancements.

4. Networking Opportunities: Connect with scholars and practitioners in vaccine research, fostering collaboration and sharing of new perspectives.

Join us at VACCINE CONGRESS 2024 for a transformative experience in vaccine research and innovation!

Visa Trip Advisor

Planning a trip to Madrid, Spain? Attend our Meeting!

Issue with VISA?

To support participants in their VISA application process, we provide VISA support documents as follows:

1. Official Letter of Invitation
2. Official Letter of Abstract Acceptance
3. Receipt of Payment

Points to note:

Visa Letter (official letter of invitation) will be issued only after successful registration and payment for the conference.
Visa Letters can be issued only for the individual accepted to attend the conference.
Please contact the Program Manager, Josephine, via vaccine@euroannualmeetings.com to arrange for a Visa Letter.

Kindly provide us with the following information for Visa Letters:

Your name as it appears on your passport
Passport Scan Copy (for passport number and date of birth)
Abstract Acceptance letter for Presenters

Payment Methods:

1. Payment Gateway/RAZORPAY
2. Bank-to-Bank transfer

Having trouble with registration?

Please contact Program Manager Josephine via vaccine@euroannualmeetings.com. The VACCINE 2024 team will provide you with an INVOICE for the requested price, enabling you to make the Bank-to-Bank transfer.

To Collaborate Scientific Professionals around the World

Conference Date September 09-10, 2024

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Vaccine Congress-2024 highlights from last year Vaccine Congress-2024 Gallery Vaccine Congress-2024 Proceedings Vaccine Congress-2024 Conference

Supported By

Journal of Clinical and Cellular Immunology Immunology: Current Research Journal of Vaccines & Vaccination Virology & Mycology

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Vaccine Research

September 09-10, 2024 Madrid, Spain

Expanding Present Vaccine Research Outcomes in the wake of Pandemic

Conference Series Conferences gaining more Readers and Visitors

Renowned Speakers

Orien L Tulp

Cecilia Castro

Caryn Fenner

Sandra Gunhild Erika Möhr

Amina Tebaa

J. Santiago Mejia

Natalia Romanenkova

Bing-Huei Chen

Recommended Global Vaccines Webinars & Conferences

Europe & UK

Asia Pacific & Middle East

Canada

VACCINE CONGRESS 2024

About VACCINE CONGRESS 2024

Why Attend?

Target Audience

Sessions & Tracks

Market Analysis

Benefits of Participation

Visa Trip Advisor

To Collaborate Scientific Professionals around the World

Useful Links

Past Conference Report

Supported By

Media partners & Collaborators & Sponsors

Keytopics